Wednesday, July 8, 2026

pharma · Asthma · Multiple Sclerosis · TEVA

Teva Pharma

Teva Biotech is a pharma organization headquartered in TEL AVIV, DE. It trades on NYSE under ticker TEVA. Primary therapeutic focus areas include Asthma, Multiple Sclerosis, Pain, Crohn's Disease, Seasonal Allergic Rhini

10 Dornierstr., Ulm, Donau, 89079, DE, TEL AVIV HQ
126 Employees
Public company Type
TEVA · NYSE Ticker
Company details
Clinical program

Deutetrabenazine Oral Capsule

Approved · small molecule · Tardive Dyskinesia

Deutetrabenazine Oral Capsule for Tardive Dyskinesia is a Approved program (small_molecule) at Teva Pharma GmbH with 1 ClinicalTrials.gov record(s).

← All Teva Pharma GmbH projects Approved small molecule active

Internal code STUDY20250619

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Teva Pharma GmbH
Phase
Approved
Modality
small_molecule
Indication
Tardive Dyskinesia
Status
active
Trials
1